The Clorox Company

NYSE:CLX 株式レポート

時価総額：US$10.9b

Clorox 将来の成長

Future 基準チェック /26

Clorox利益と収益がそれぞれ年間8.1%と5.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に224.7% 10.7%なると予測されています。

主要情報

8.1%

収益成長率

10.68%

EPS成長率

Household Products 収益成長5.4%
収益成長率5.4%
将来の株主資本利益率224.70%
アナリストカバレッジ

Good

最終更新日04 May 2026

今後の成長に関する最新情報

分析記事 • Aug 02

Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...

Recent updates

ナラティブ更新 • Apr 29

CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple

Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.
Seeking Alpha • Apr 28

Clorox: Reduced Complexity Paves The Way For Multiple Expansion

Summary Clorox is attractively valued after underperformance, offering a 5% dividend yield and normalization post-cyber attack and ERP disruptions. The recent Purell (GOJO) acquisition is set to be accretive to EBITDA and EPS by FY27, supporting top-line growth above the company's long-term algorithm. CLX trades at 14.5x FY27 EPS, with double-digit earnings growth and room for multiple expansion relative to peers, setting up 20% upside potential. Risks include high customer concentration, private label competition, and consumer value-seeking behavior, but strong cash flow supports deleveraging and dividend sustainability. Read the full article on Seeking Alpha
ナラティブ更新 • Apr 15

CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power

Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.
ナラティブ更新 • Mar 31

CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power

Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.
ナラティブ更新 • Mar 17

CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook

Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.
ナラティブ更新 • Mar 03

CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power

Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.
ナラティブ更新 • Feb 17

CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E

The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.
ナラティブ更新 • Feb 03

CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple

Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.
ナラティブ更新 • Jan 20

CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating

Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.
ナラティブ更新 • Jan 05

CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating

Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.
ナラティブ更新 • Dec 20

CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook

Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.
ナラティブ更新 • Dec 05

CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery

Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.
ナラティブ更新 • Nov 21

CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026

Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.
分析記事 • Nov 12

Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet

Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...
分析記事 • Nov 10

Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues

The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...
ナラティブ更新 • Nov 06

CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026

Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.
ナラティブ更新 • Oct 23

Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook

Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.
ナラティブ更新 • Oct 09

Modern ERP And Digital Marketing Will Unlock Lasting Opportunities

Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.
ナラティブ更新 • Aug 27

Modern ERP And Digital Marketing Will Unlock Lasting Opportunities

Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.
分析記事 • Aug 04

Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24

The Clorox Company ( NYSE:CLX ) will increase its dividend on the 29th of August to $1.24, which is 1.6% higher than...
分析記事 • Aug 02

Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...
分析記事 • Jul 16

Returns On Capital At Clorox (NYSE:CLX) Have Stalled

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Seeking Alpha • Mar 29

Clorox: Reviving From Cyberattack; Initiate With 'Buy'

Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Clorox: A Wonderful Business I Would Like To Own At A Lower Price

Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking Alpha
Seeking Alpha • Nov 26

The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals

Summary I rate The Clorox Company a hold due to its volatile financial performance and current stock trading above fair value. Despite revenue fluctuations, Clorox has strong brand recognition and promising growth potential, with 80% of sales from top-ranked products. The company's resilience is evident through consistent dividends, high ROE, ROCE, and positive EVA, indicating shareholder value creation. Clorox's recovery is marked by significant YoY growth in revenue, net income, and operational efficiency, showcasing potential for future growth. Read the full article on Seeking Alpha

業績と収益の成長予測

NYSE:CLX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
6/30/20287,7968258481,0769
6/30/20277,5777828521,06112
6/30/20266,68459275876710
3/31/20266,760756380576N/A
12/31/20256,758755778984N/A
9/30/20256,771791636853N/A
6/30/20257,104810761981N/A
3/31/20257,0196948011,027N/A
12/31/20247,165457695923N/A
9/30/20247,469357669896N/A
6/30/20247,093280483695N/A
3/31/20247,209240570785N/A
12/31/20237,31080728944N/A
9/30/20237,035867941,000N/A
6/30/20237,3891499301,158N/A
3/31/20237,171748401,063N/A
12/31/20227,065435721951N/A
9/30/20227,041405678923N/A
6/30/20227,107462535786N/A
3/31/20227,108458563834N/A
12/31/20217,080247580869N/A
9/30/20217,231437620934N/A
6/30/20217,3417109451,276N/A
3/31/20217,5229231,3051,633N/A
12/31/20207,5241,2251,3831,677N/A
9/30/20207,1311,1511,3891,658N/A
6/30/20206,7219391,2921,546N/A
3/31/20206,3658709661,195N/A
12/31/20196,133816N/A1,041N/A
9/30/20196,157813N/A1,004N/A
6/30/20196,214820N/A992N/A
3/31/20196,278796N/A1,003N/A
12/31/20186,244790N/A1,101N/A
9/30/20186,187841N/A975N/A
6/30/20186,124823N/A976N/A
3/31/20186,080808N/A962N/A
12/31/20176,040799N/A922N/A
9/30/20176,030716N/A958N/A
6/30/20175,973703N/A865N/A
3/31/20175,926666N/A813N/A
12/31/20165,875653N/A863N/A
9/30/20165,814654N/A801N/A
6/30/20165,761648N/A778N/A
3/31/20165,718672N/A826N/A
12/31/20155,693657N/A782N/A
9/30/20155,693634N/A778N/A
6/30/20155,655606N/A874N/A

アナリストによる今後の成長予測

収入対貯蓄率: CLXの予測収益成長率 (年間8.1% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: CLXの収益 ( 8.1% ) US市場 ( 16.6% ) よりも低い成長が予測されています。

高成長収益: CLXの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: CLXの収益 ( 5.4% ) US市場 ( 11.5% ) よりも低い成長が予測されています。

高い収益成長: CLXの収益 ( 5.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CLXの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 224.7 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/07 00:37
終値2026/05/07 00:00
収益2026/03/31
年間収益2025/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

The Clorox Company 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35

アナリスト機関
John StaszakArgus Research Company
Lauren LiebermanBarclays
Lauren LiebermanBarclays